Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.88 USD -0.04 ( 2.08%)
Last update at 2026-11-06T21:00:00Z
VOLUME
57931
Market Cap
29.11M

Momentum Score

…

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.88
Low
1.99
High
52 Week Price Range
0.16
Low
1.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on SeaStar Medical Holding Corporation (NASDAQ: ICU) is limited. Available disclosures identify it as a medical device company, and its long-term growth drivers may include aging population trends, increasing demand for minimally invasive therapies, and successful regulatory approvals and commercial adoption. Investors may find exposure to the procedural device market and potential recurring revenue from consumable products attractive if commercialization progresses.
Key risks include limited public disclosure and operating history, regulatory and reimbursement uncertainty, execution and commercialization risk, competitive pressures, and potential need for additional capital.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.92
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.65
ROE
-
Net Debt
8.90M
ROCE
121.78%
Diluted EPS TTM
-0.88

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -23.01M -4.60M -3.27M
Net income -23.01M -4.60M -3.28M
Selling general administrative 6.60M 1.68M 2.43M
Ebit - -4.45M -6.45M
Ebitda -11.61M -4.36M -6.37M
Depreciation and amortization - 0.09M 0.08M
Operating income -11.61M -4.45M -6.45M
Other operating expenses 11.61M 4.45M 6.45M
Interest expense 0.63M 0.21M 3.31M
Tax provision 0.00M -0.00M 0.01M
Net interest income -0.63M -0.21M -3.31M
Income tax expense 0.00M -0.00M 0.01M
Total revenue 0.00M 0.00M 0.00M
Total operating expenses 11.61M 4.45M 6.45M
Total other income expense net -10.77M 0.06M 6.49M
Net income from continuing ops -23.01M -4.60M -3.28M
Net income applicable to common shares - -4.60M -3.28M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 3.51M 4.77M 0.60M 2.91M
Other current assets 2.13M - - -
Total liab 17.38M 13.00M 76.77M 74.49M
Total stockholder equity -13.87M -8.23M -76.17M -71.58M
Other current liab 8.97M 2.25M 0.66M 0.68M
Common stock 0.01M 0.00M - -
Capital stock 0.01M 0.00M 0.00M 0.00M
Retained earnings -114.73M -99.33M -76.31M -71.72M
Other liab - - 0.06M -
Other assets - - 0.00M 0.00M
Cash 0.18M 0.05M 0.51M 2.81M
Total current liabilities 13.05M 5.35M 3.12M 1.08M
Current deferred revenue -5.04M - 0.19M -
Net debt 8.90M 8.78M 2.11M -2.72M
Short term debt 4.74M 1.18M 2.38M 0.02M
Short long term debt 4.74M 1.18M 2.38M 0.02M
Short long term debt total 9.08M 8.83M 2.62M 0.08M
Other stockholder equity 100.86M 91.09M 0.15M 0.13M
Total current assets 2.31M 3.04M 0.60M 2.91M
Net tangible assets - - -76.17M -71.58M
Net receivables - 0.01M 0.06M -
Long term debt 4.34M 7.65M 0.24M 0.06M
Inventory - - 0.00M 0.06M
Accounts payable 4.37M 1.93M 0.09M 0.38M
Non currrent assets other 1.21M 1.73M 0.00M 0.00M
Non current assets total 1.21M 1.73M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Change to liabilities - -0.30M 0.23M
Net borrowings - 2.82M -0.13M
Total cash from financing activities 7.33M 2.82M 4.89M
Change to operating activities - -0.44M 0.53M
Net income -23.01M -4.60M -3.28M
Change in cash -0.46M -2.30M -0.68M
Begin period cash flow 0.51M 2.81M 3.49M
End period cash flow 0.05M 0.51M 2.81M
Total cash from operating activities -7.79M -5.11M -5.57M
Issuance of capital stock 10.00M 0.00M 5.03M
Change to inventory 0.00M 0.06M 0.14M
Other cashflows from financing activities -2.59M 2.84M 5.19M
Change to netincome - 0.16M -3.42M
Capital expenditures 0.00M 0.00M 0.00M
Change in working capital 2.55M -0.68M 0.89M
Stock based compensation 1.31M 0.01M 0.00M
Other non cash items 11.36M 0.15M -3.19M
Free cash flow -7.79M -5.11M -5.57M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ICU
SeaStar Medical Holding Corporation		 -0.04
2.08%		 1.88 - - - - -1.64
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

SeaStar Medical Holding Corporation

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.

3513 Brighton Boulevard, Denver, CO, United States, 80216

844 427 8100

https://www.seastarmedical.com

12

Name Title Year Born
Mr. Eric Schlorff CEO, Pres & Director 1973
Dr. H. David Humes M.D. Co-Founder and Managing Director NA
Ms. Caryl Baron Interim Chief Financial Officer 1967
Tom Mullen VP of Operations & Product Devel. NA
Colonel Kevin Chung FACP, M.D. Chief Medical Officer 1972
Mr. Eric Schlorff CEO, President & Executive Director 1973
Colonel Kevin Chung FACP, M.D. Chief Medical Officer 1973
Mr. David A. Green CPA, M.B.A. Chief Financial Officer 1963
Tom Mullen Vice President of Operations & Product Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…